Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- GlaucomaOcular Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 207
- Registration Number
- NCT00168363
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Biological: Botulinum Toxin Type AOther: Placebo (saline)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 679
- Registration Number
- NCT00156910
A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%
Phase 3
Completed
- Conditions
- Acne Vulgaris
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 301
- Registration Number
- NCT00151541
Evaluation of Eflornithine on Facial and Forearm Skin
Phase 4
Completed
- Conditions
- Hirsutism
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 78
- Registration Number
- NCT00152048
Memantine in Patients With Chronic Glaucoma
Phase 3
Completed
- Conditions
- Open-Angle Glaucoma
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1119
- Registration Number
- NCT00141882
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
Phase 2
Completed
- Conditions
- StrokeMuscle SpasticityMotor Neuron Disease
- Interventions
- Biological: botulinum toxin Type ADrug: saline
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 155
- Registration Number
- NCT00076687
Research Study in Patients With Persistent Macular Edema
Phase 2
Completed
- Conditions
- DiabetesMacular EdemaDiabetic RetinopathyRetinal DiseaseUveitis, Posterior
- First Posted Date
- 2002-05-07
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 315
- Registration Number
- NCT00035906
- Locations
- 🇺🇸
Oculex Pharmaceuticals, Sunnyvale, California, United States
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
Phase 3
Completed
- Conditions
- Keratoconjunctivitis SiccaSjogren's SyndromeLupus Erythematosus, SystemicArthritis, RheumatoidScleroderma, Systemic
- First Posted Date
- 2001-10-29
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 290
- Registration Number
- NCT00025818
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Eyecare of La Jolla, La Jolla, California, United States
© Copyright 2025. All Rights Reserved by MedPath